10-Q: Dyadic International Reports Q1 2024 Results, Bolstered by $6 Million Capital Raise and Strategic Partnerships

Dyadic International's Q1 2024 report highlights a net loss of $2 million alongside a strategic $6 million capital raise and advancements in its C1 protein production platform for both pharmaceutical and non-pharmaceutical applications.

Summary

• Dyadic International, Inc. reported a net loss of $2,009,596 for the first quarter of 2024, compared to a net loss of $956,444 in the same period of 2023.
• The increased loss was primarily due to the sale of the company's equity interest in Alphazyme LLC for $989,000 in 2023.
• Revenue for Q1 2024 was $334,617, down from $978,052 in Q1 2023, attributed to the winding down of several large research collaborations.
• The company successfully raised $6 million through the issuance of 8.0% Senior Secured Convertible Promissory Notes due March 8, 2027.
• Dyadic is focusing on developing its microbial protein production platforms, C1 and Dapibus, for various applications, including vaccines, therapeutic proteins, and alternative proteins.
• The company announced several new collaborations and partnerships in both the human and animal health sectors, as well as the alternative proteins sector.
• Dyadic's Phase 1 clinical trial for its DYAI-100 COVID-19 vaccine candidate met its primary endpoint of safety and reactogenicity.
• The company is also advancing its animal-free recombinant albumin projects and has entered into a co-promotion agreement with Biftek Co. for growth media supplements.
• Dyadic's management believes that existing cash, cash equivalents, investments, and operating cash flows will be sufficient to meet operational needs for at least the next 12 months.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the increased net loss and revenue decline. However, the successful capital raise, positive clinical trial results, and new partnerships provide some optimism for the future.

Positives

• Successful $6 million capital raise strengthens financial position.
• Positive safety results from the Phase 1 clinical trial of the DYAI-100 COVID-19 vaccine candidate.
• Multiple new collaborations and partnerships in the human and animal health sectors.
• Strategic partnership with Cygnus Technologies for C1 Host Cell Protein ELISA Kit.
• Progress in animal-free recombinant albumin projects.
• Co-promotion agreement with Biftek Co. for growth media supplements.
• Advancements in non-animal dairy enzyme development and commercialization.
• Development of a highly productive strain for recombinant alpha-lactalbumin.
• Ongoing projects for beta-lactoglobulin and lactoferrin recombinant proteins.
• Development of three enzymes with potential use in multiple industries.

Negatives

• Net loss increased in Q1 2024 compared to Q1 2023.
• Revenue decreased in Q1 2024 compared to Q1 2023.
• Winding down of several large research collaborations.
• Dependence on third-party collaborations and licensing agreements for revenue generation.

Risks

• The company has a history of net losses and expects to incur losses and have negative cash flows as it continues developing its platforms.
• The success of the company depends on its ability to develop its technologies to the point of regulatory approval and subsequent revenue generation.
• The company may need to raise additional capital in the future, which could be dilutive to existing shareholders.
• Market and regulatory acceptance of the company's microbial protein production platforms is uncertain.
• Competition from alternative technologies could impact the company's success.
• The results of nonclinical and clinical trials may not be positive.
• Changes in global economic and financial conditions could adversely affect the company.
• The company relies on information technology, and any disruptions could harm its operations.
• The company is dependent on third parties for various aspects of its business.
• Government regulations and environmental, social, and governance issues could impact the company.

Future Outlook

The company expects its existing cash and cash equivalents, cash raised from the Convertible Notes, investments in debt securities, and operating cash flows will be sufficient to meet its operational, business, and other liquidity requirements for at least the next twelve (12) months. However, the company has based this estimate on assumptions that may prove to be wrong, and its operating plan may change as a result of many factors currently unknown to it.

Management Comments

• This private placement funding will support our near-term revenue growth and accelerate our strategic objective of commercialization opportunities for pharmaceutical and non-pharmaceutical applications.

Industry Context

Dyadic's focus on microbial protein production aligns with the growing demand for sustainable and cost-effective manufacturing methods in the biopharmaceutical and alternative protein industries. The company's C1 and Dapibus platforms offer potential advantages over traditional cell culture systems, such as higher yields, faster production times, and lower costs. The increasing interest in animal-free products and the need for rapid vaccine development further highlight the relevance of Dyadic's technologies.

Comparison to Industry Standards

• Dyadic's C1 protein production platform is being positioned as a potential alternative to traditional mammalian cell culture systems, such as those used by companies like Lonza, Boehringer Ingelheim, and Samsung Biologics.
• Compared to these established players, Dyadic's technology is still in the early stages of commercialization but offers potential advantages in terms of cost and scalability.
• In the alternative protein space, Dyadic's Dapibus platform competes with other microbial fermentation approaches used by companies like Perfect Day, Geltor, and Motif FoodWorks.
• Dyadic's recombinant albumin products are comparable to reference standards used in the industry, suggesting they could be competitive with existing products from companies like Sigma-Aldrich and Thermo Fisher Scientific.
• The company's focus on non-animal dairy enzymes aligns with the growing market for plant-based and cell-based dairy alternatives, where companies like Novozymes and DSM are also active.

Management Changes

Legal Proceedings

• The company is not currently involved in any litigation that it believes could have a materially adverse effect in our financial condition or results of operations.

Related Party Transactions

• The purchasers of the Convertible Notes include immediate family members and family trusts related to Mark Emalfarb, our President and Chief Executive Officer and a member of our Board of Directors, including The Francisco Trust, an existing holder of more than 5% of the Company's outstanding common stock.

Stakeholder Impact

• Shareholders: Potential dilution from the conversion of the Convertible Notes. The company's future success depends on its ability to generate revenue and achieve profitability, which could positively impact shareholder value.
• Employees: Continued employment and potential growth opportunities as the company expands its operations and develops its technologies.
• Customers: Potential access to innovative and cost-effective products developed using Dyadic's platforms.
• Suppliers: Potential for increased business as Dyadic scales up its production and development activities.
• Creditors: The issuance of the Convertible Notes increases the company's debt obligations.

Next Steps

• Continue developing the C1 and Dapibus platforms for various applications.
• Advance the DYAI-100 COVID-19 vaccine candidate and other vaccine and therapeutic protein projects.
• Further develop and commercialize animal-free recombinant albumin products.
• Progress the development and commercialization of non-animal dairy enzymes.
• Sample recombinant alpha-lactalbumin and negotiate development and commercialization agreements.
• Begin sampling beta-lactoglobulin and lactoferrin recombinant proteins.
• Evaluate and pursue opportunities for bio-industrial enzymes.

Key Dates

Keywords

Dyadic International, biotechnology, protein production, C1 platform, Dapibus platform, microbial, vaccine, therapeutic proteins, monoclonal antibodies, alternative proteins, recombinant albumin, non-animal dairy, enzymes, clinical trial, collaboration, licensing, capital raise, convertible notes